Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)

Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s endogenous immunity in his or her fight agains...

Full description

Saved in:
Bibliographic Details
Main Authors: ON Solopova, VA Misyurin
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2019-03-01
Series:Клиническая онкогематология
Subjects:
Online Access: http://bloodjournal.ru/wp-content/uploads/2019/03/3-3.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850251251887898624
author ON Solopova
VA Misyurin
author_facet ON Solopova
VA Misyurin
author_sort ON Solopova
collection DOAJ
description Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s endogenous immunity in his or her fight against tumor. The present review covers all the formats and strategies used in engineering of bispecific antibodies which reached the stage of clinical trials and also focuses on the available results of these clinical trials.
format Article
id doaj-art-80a3c10d6d894ef5ba03f2a60973dd4b
institution OA Journals
issn 1997-6933
2500-2139
language Russian
publishDate 2019-03-01
publisher Practical Medicine Publishing House
record_format Article
series Клиническая онкогематология
spelling doaj-art-80a3c10d6d894ef5ba03f2a60973dd4b2025-08-20T01:57:56ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392019-03-0112212514410.21320/2500-2139-2019-12-2-125-14419976933Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)ON Solopova0VA Misyurin1 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478 Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s endogenous immunity in his or her fight against tumor. The present review covers all the formats and strategies used in engineering of bispecific antibodies which reached the stage of clinical trials and also focuses on the available results of these clinical trials. http://bloodjournal.ru/wp-content/uploads/2019/03/3-3.pdf bispecific antibodiesblinatumomabcatumaxomabemicizumabclinical trial
spellingShingle ON Solopova
VA Misyurin
Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
Клиническая онкогематология
bispecific antibodies
blinatumomab
catumaxomab
emicizumab
clinical trial
title Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
title_full Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
title_fullStr Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
title_full_unstemmed Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
title_short Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
title_sort bispecific antibodies in clinical practice and clinical trials literature review
topic bispecific antibodies
blinatumomab
catumaxomab
emicizumab
clinical trial
url http://bloodjournal.ru/wp-content/uploads/2019/03/3-3.pdf
work_keys_str_mv AT onsolopova bispecificantibodiesinclinicalpracticeandclinicaltrialsliteraturereview
AT vamisyurin bispecificantibodiesinclinicalpracticeandclinicaltrialsliteraturereview